In Silico-Based Design and In Vivo Evaluation of an Anthranilic Acid Derivative as a Multitarget Drug in a Diet-Induced Metabolic Syndrome Model

Abstract

Metabolic syndrome (MetS) is a complex disease that affects almost a quarter of the world’s adult population. In MetS, diabetes, obesity, hyperglycemia, high cholesterol, and high blood pressure are the most common disorders. Polypharmacy is the most used strategy for managing conditions related to MetS, but it has drawbacks such as low medication adherence. Multitarget ligands have been proposed as an interesting approach to developing drugs to treat complex diseases. However, suitable preclinical models that allow their evaluation in a context closer to a clinical situation of a complex disease are needed. From molecular docking studies, compound 1b, a 5-aminoanthranilic acid derivative substituted with 4′-trifluoromethylbenzylamino and 3′,4′-dimethoxybenzamide moieties, was identified as a potential multitarget drug, as it showed high in silico affinity against targets related to MetS, including PPAR-α, PPAR-γ, and HMG-CoA reductase. It was evaluated in a diet-induced MetS rat model and simultaneously lowered blood pressure, glucose, total cholesterol, and triglyceride levels after a 14-day treatment. No toxicity events were observed during an acute lethal dose evaluation test at 1500 mg/kg. Hence, the diet-induced MetS model is suitable for evaluating treatments for MetS, and compound 1b is an attractive starting point for developing multitarget drugs.

Quercetin and Kaempferol as Multi-Targeting Antidiabetic Agents against Mouse Model of Chemically Induced Type 2 Diabetes

“…Multi-target drugs hold promise in addressing intricate conditions such as diabetes, captivating the interest of researchers. Since 2015, the FDA has increasingly approved such drugs, indicating their growing importance in pharmaceutical research [ 51 ]. Bioactive compounds derived from medicinal plants offer a promising option for the management of different ailments with fewer side effects.…”

In Silico and In Vivo Evaluation of the Maqui Berry (Aristotelia chilensis (Mol.) Stuntz) on Biochemical Parameters and Oxidative Stress Markers in a Metabolic Syndrome Model

“…One study found that levels of oxidative stress markers were decreased by 50 mg/kg MB, and the decrease in oxidative stress markers was maintained up to the 100 mg/kg MB dose [15]. In addition, some polyphenols such as epigallocatechin-3-gallate have been observed to improve insulin resistance by promoting glucose uptake and the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase, attenuating oxidative stress and the inflammatory markers malondialdehyde, tumor necrosis factor 1 alpha (TNF-α), interleukin 6 (IL-6), and nuclear factor kappa beta (NF-κβ) [33].…”

Jatrorrhizine: A Review of Sources, Pharmacology, Pharmacokinetics and Toxicity

“…However, major problems of this therapeutic method are poor patient compliance, side effects and drug-drug interactions ( Lillich et al, 2021 ). Multi-target ligands and drugs have been proposed as promising approaches to developing therapies for complex diseases ( González-Álvarez et al, 2021 ). Jatrorrhizine is a multi-purpose natural metabolite that affects multiple targets.…”